Table 9.

Atherosclerotic Cardiovascular Disease Risk Categories, Characteristics, Lipid Targets, and Therapy^a

Risk categories	Risk characteristics	Approximate 10-y risk	Lipid targets	Therapy
High risk	T2D duration <10 y, T1D duration <20 y with <2 additional ASCVD risk factors; no TOD	<10%	LDL-C <100 mg/dL; apo B <90 mg/dL; non-HDL-C <130 mg/dL	Moderate-intensity statin to start, intensify as needed
Very high risk	T2D duration >10 y or T1D >20 y and age >40 y without ASCVD or severe TOD; ≥2 additional traditional ASCVD risk factors	10% to 20%	LDL-C <70 mg/dL; apo B <80 mg/dL; non-HDL-C <100 mg/dL	High-intensity statin, addition of ezetimibe or bempedoic acid to reach lipid targets
Extreme risk	T2D or T1D with established ASCVD or severe TOD: eGFR <45 mL/min/1.73 m2; UACR >300 mg/g; ABI <0.9; left ventricular systolic or diastolic dysfunction	>20%	LDL-C <55 mg/dL; apo B <70 mg/dL; non-HDL-C <90 mg/dL	High-intensity statin, addition of ezetimibe, bempedoic acid, and/or PCSK9 agent to reach lipid targets

Abbreviations: ABI = ankle-brachial index; apo B = apolipoprotein B-100; ASCVD = atherosclerotic cardiovascular disease; eGFR = estimated glomerular filtration rate; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; T1D = type 1 diabetes; T2D = type 2 diabetes; TOD = target organ damage (left ventricular systolic or diastolic dysfunction, eGFR <45 mL/min/1.73 m², and abnormal ankle-brachial index); UACR = urine albumin-to-creatinine ratio

^aTask force expert opinion